ICON shares jump as Anthropic partnership and CRO optimism lift sentiment

ICON plc (ICLR) is up 7.0% today. Here is some analysis on what might have caused this price movement.

Analysis: The clearest catalyst appears to be ICON’s July 28 announcement of a multi-year collaboration with Anthropic to use Claude across the clinical trial lifecycle. The move also may be getting help from improving sentiment toward contract research companies after a major peer posted a strong quarter on the same day, which likely raised expectations ahead of ICON’s own second-quarter results.

Details:

ICON announced a new multi-year AI collaboration with Anthropic on July 28 focused on applying Claude across trial design, document workflows, data review, and other parts of clinical development.

The company had already been leaning into AI-enabled clinical development, including a June partnership with Microsoft, so investors may be viewing the Anthropic deal as another sign that management is accelerating that strategy.

ICON is scheduled to release second-quarter 2026 results after the market close on July 29, with the earnings call set for July 30, putting extra attention on any news that could shape expectations.

Sector read-through likely helped as well: a large peer in clinical research reported second-quarter revenue growth, stronger bookings, and raised full-year guidance on July 28, which could be reinforcing optimism for the group.

Sources:

ICON plc, IQVIA

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$ICLR Hedge Fund Activity

We have seen 204 institutional investors add shares of $ICLR stock to their portfolio, and 270 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

ORBIS ALLAN GRAY LTD removed 4,214,661 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $466,394,386
BRAVE WARRIOR ADVISORS, LLC added 2,996,811 shares (+inf%) to their portfolio in Q1 2026, for an estimated $331,627,105
NINETY ONE UK LTD removed 2,945,810 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $325,983,334
FRANKLIN RESOURCES INC removed 2,177,251 shares (-72.7%) from their portfolio in Q1 2026, for an estimated $240,934,595
GREENHAVEN ASSOCIATES INC added 1,985,017 shares (+11412.1%) to their portfolio in Q1 2026, for an estimated $219,661,981
HARRIS ASSOCIATES L P added 1,841,151 shares (+73.3%) to their portfolio in Q1 2026, for an estimated $203,741,769
WELLINGTON MANAGEMENT GROUP LLP added 1,562,287 shares (+35.9%) to their portfolio in Q1 2026, for an estimated $172,882,679

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$ICLR Congressional Stock Trading

Members of Congress have traded $ICLR stock 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $ICLR stock by members of Congress over the last 6 months:

REPRESENTATIVE KEVIN HERN sold up to $250,000 on 03/05.
REPRESENTATIVE JULIA LETLOW sold up to $15,000 on 02/12.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$ICLR Price Targets

Multiple analysts have issued price targets for $ICLR recently. We have seen 12 analysts offer price targets for $ICLR in the last 6 months, with a median target of $182.5.

Here are some recent targets:

Jailendra Singh from Truist Securities set a target price of $207.0 on 06/30/2026
Ann Hynes from Mizuho set a target price of $190.0 on 06/26/2026
Michael Ryskin from B of A Securities set a target price of $150.0 on 06/25/2026
Eric Coldwell from Baird set a target price of $186.0 on 06/25/2026
Ross Muken from Evercore ISI Group set a target price of $180.0 on 06/25/2026
Luke Sergott from Barclays set a target price of $175.0 on 06/25/2026
Ryan Halsted from RBC Capital set a target price of $185.0 on 06/25/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.